CR11518A - Compuestos de carbamoilo como inhibidores de dgat1 190 - Google Patents

Compuestos de carbamoilo como inhibidores de dgat1 190

Info

Publication number
CR11518A
CR11518A CR11518A CR11518A CR11518A CR 11518 A CR11518 A CR 11518A CR 11518 A CR11518 A CR 11518A CR 11518 A CR11518 A CR 11518A CR 11518 A CR11518 A CR 11518A
Authority
CR
Costa Rica
Prior art keywords
compounds
carbamoil
dgat1
inhibitors
dgat
Prior art date
Application number
CR11518A
Other languages
English (en)
Inventor
Udo Andreas Bauer
Ala Martin Birch
Roger John Butlin
Clive Green
Jonas Gunnar Barlind
Ragnar Hovland
Petra Johannesson
Jan Magnus Johansson
Andrew Leach
Alexander Tobias Noeske
Annika Ulrika Peterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11518(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11518A publication Critical patent/CR11518A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Se describen compuestos inhibidores de DGAT-1 de la formula (I), sales aceptables para uso farmaceuticos y prodrogas de los mismo junto con composiciones farmaceuticas.
CR11518A 2007-12-20 2010-06-18 Compuestos de carbamoilo como inhibidores de dgat1 190 CR11518A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1539707P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
CR11518A true CR11518A (es) 2010-07-15

Family

ID=40427160

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11518A CR11518A (es) 2007-12-20 2010-06-18 Compuestos de carbamoilo como inhibidores de dgat1 190

Country Status (23)

Country Link
US (2) US7994179B2 (es)
EP (1) EP2234978B1 (es)
JP (1) JP5662803B2 (es)
KR (1) KR20100099738A (es)
CN (1) CN101932562B (es)
AR (1) AR069802A1 (es)
AU (1) AU2008339570B2 (es)
BR (1) BRPI0821274A2 (es)
CA (1) CA2707660A1 (es)
CL (1) CL2008003847A1 (es)
CO (1) CO6290685A2 (es)
CR (1) CR11518A (es)
DO (1) DOP2010000192A (es)
EA (1) EA201001015A1 (es)
EC (1) ECSP10010274A (es)
ES (1) ES2535083T3 (es)
IL (1) IL206045A0 (es)
NI (1) NI201000108A (es)
NZ (1) NZ586104A (es)
PE (1) PE20091682A1 (es)
TW (1) TW200932235A (es)
WO (1) WO2009081195A1 (es)
ZA (1) ZA201003979B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) * 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
SI2402317T1 (sl) 2006-03-31 2013-10-30 Novartis Ag DGAT inhibitor
AU2007266796B2 (en) 2006-05-30 2011-02-10 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
KR20090010092A (ko) * 2006-05-30 2009-01-28 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 1,3,4-옥사디아졸 유도체
ES2359653T3 (es) * 2006-06-08 2011-05-25 Astrazeneca Ab Bencimidazoles y su uso para el tratamiento de la diabetes.
JP5203360B2 (ja) 2006-06-23 2013-06-05 アボット・ラボラトリーズ ヒスタミンｈ３受容体調節剤としてのシクロプロピルアミン誘導体
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0815490A2 (pt) * 2007-08-17 2017-03-21 Astrazeneca Ab composto, composição faramcêutica, método para tratar diabetes mellitus e/ou obesidade em um animal de sangue quente, e, processo para preparar um composto
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
AU2009329345A1 (en) * 2008-12-19 2011-06-30 Astrazeneca Ab 1,3,4-oxadiazole derivatives and their uses to treat diabetes
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
KR20120037939A (ko) 2009-06-19 2012-04-20 아스트라제네카 아베 Ｄｇａｔ１의 억제제로서 피라진 카르복사미드
WO2011054530A1 (en) * 2009-11-05 2011-05-12 Fibrostatin, S.L. Gpbp inhibition using q2 peptidomimetics
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012064569A1 (en) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Imidazole derivatives
US9045389B2 (en) * 2011-05-23 2015-06-02 Janssen Pharmaceutica Nv Biphenyl derivatives useful as glucagon receptor antagonists
TW201307287A (zh) * 2011-05-30 2013-02-16 Daiichi Sankyo Co Ltd 環烷基氧基聯芳基型化合物
WO2013068328A1 (en) * 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
CN104245696A (zh) * 2012-02-07 2014-12-24 凯诺斯医药公司 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
AP3592A (en) * 2012-04-27 2016-02-15 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors.
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US8962660B2 (en) * 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
KR102225715B1 (ko) * 2013-07-09 2021-03-09 토소가부시키가이샤 아다만틸기를 가진 환상 아진 화합물, 제조 방법, 및 상기 화합물을 구성 성분으로서 함유하는 유기 전계발광소자
CA2931313C (en) 2013-11-21 2022-04-05 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
ES2881706T3 (es) * 2014-03-12 2021-11-30 Astrazeneca Ab Método de tratamiento de las afecciones de la piel
CA3101064A1 (en) * 2018-06-21 2019-12-26 Dermavant Sciences GmbH Topical formulations of dgat1 inhibitors and their methods of use
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020214693A1 (en) * 2019-04-17 2020-10-22 Ixchel Pharma, Llc Prodrugs of monomethyl fumarate

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3245989A (en) 1962-12-15 1966-04-12 Acraf 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles
US4983731A (en) 1989-03-17 1991-01-08 Nebraska Department Of Economic Development Separation and purification of sugar esters
US5491172A (en) 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
AU2856499A (en) 1999-03-25 2000-10-16 Kitasato Institute, The Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CA2369967A1 (en) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
JP2002284741A (ja) 2001-03-23 2002-10-03 Kitasato Inst:The ローズリピン誘導体
RS50889B (sr) 2001-08-31 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Derivati diaril-cikloalkila, postupak za njihovu proizvodnju i njihova primena u svojstvu ppar aktivatora
DE10223273A1 (de) 2002-05-24 2003-12-04 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1448556A1 (en) * 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
JP2006502247A (ja) 2002-07-12 2006-01-19 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 複素環で置換されたベンゾイル尿素、その製造方法および医薬としてのその使用
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
JP2005536554A (ja) 2002-08-23 2005-12-02 ユニバーシティ オブ コネチカット 新規なビフェニル及びビフェニル様カンナビノイド
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
AU2003287178A1 (en) 2002-10-10 2004-05-04 Smithkline Beecham Corporation Chemical compounds
MXPA05005425A (es) 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
CN102267924A (zh) 2003-01-08 2011-12-07 诺华疫苗和诊断公司 抗菌剂
JP4847314B2 (ja) 2003-04-07 2011-12-28 コーティカル・ピーティーワイ・リミテッド 炎症性疾患を治療するための新規な方法
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
US20050143464A1 (en) 2003-09-22 2005-06-30 Use-Techno Corporation Insulin secretion potentiator
JP4956191B2 (ja) 2003-10-17 2012-06-20 インサイト コーポレーション マトリックスメタロプロテイナーゼの阻害剤としての置換環状ヒドロキサメート
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
US20050101660A1 (en) 2003-11-11 2005-05-12 The Skinny Drink Company Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US20070249620A1 (en) 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1805156B1 (en) 2004-10-15 2010-12-22 Bayer HealthCare LLC Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2006054370A1 (en) 2004-11-16 2006-05-26 Use-Techno Corporation Gluconeogenesis inhibiting agent
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
EP1845081A4 (en) 2005-02-01 2009-03-25 Takeda Pharmaceutical amide
AU2006210056A1 (en) 2005-02-07 2006-08-10 F. Hoffmann-La Roche Ag Inhibitors of diacylglycerol acyltransferase (DGAT)
US20090215780A1 (en) 2005-04-19 2009-08-27 Bayer Pharmaceuticals Corporation Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity
JP2008540485A (ja) 2005-05-10 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ジアシルグリセロールアシルトランスフェラーゼ阻害剤
CA2610188A1 (en) 2005-06-11 2006-12-21 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
EP1912634A4 (en) 2005-07-29 2010-06-09 Bayer Healthcare Llc PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
JP2007131584A (ja) 2005-11-11 2007-05-31 Sankyo Co Ltd 新規ベンゾオキサゾール誘導体
WO2007060140A2 (en) 2005-11-28 2007-05-31 F. Hoffmann-La Roche Ag Inhibitors of diacyglycerol acyltransferase (dgat)
JP2007191471A (ja) 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
WO2007074753A1 (ja) 2005-12-27 2007-07-05 Daiichi Sankyo Company, Limited 置換されたウレア誘導体を含有する医薬
SI2402317T1 (sl) 2006-03-31 2013-10-30 Novartis Ag DGAT inhibitor
EP2016047B1 (en) 2006-04-21 2013-08-28 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
WO2007137103A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
AU2007266796B2 (en) 2006-05-30 2011-02-10 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
KR20090010092A (ko) 2006-05-30 2009-01-28 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 1,3,4-옥사디아졸 유도체
JP2009539816A (ja) 2006-06-06 2009-11-19 アストラゼネカ アクチボラグ 化学化合物
ES2359653T3 (es) 2006-06-08 2011-05-25 Astrazeneca Ab Bencimidazoles y su uso para el tratamiento de la diabetes.
GB0611507D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
EP2044055A4 (en) 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
US7569590B2 (en) 2006-09-19 2009-08-04 Bristol-Myers Squibb Company Use of thianecarboxamides as dgat inhibitors
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
EP2084146B1 (en) 2006-10-04 2013-08-21 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
BRPI0717845A2 (pt) 2006-10-04 2015-06-16 Hoffmann La Roche Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
JP2010510177A (ja) 2006-11-17 2010-04-02 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害を治療するための化合物および方法
JP2010511058A (ja) 2006-11-29 2010-04-08 アボット・ラボラトリーズ ジアシルグリセロールｏ−アシルトランスフェラーゼ１型酵素の阻害薬
MX2009006171A (es) 2006-12-11 2009-06-19 Novartis Ag Metodo para la prevencion o el tratamiento de isquemia de miocardio.
EP2120911A1 (en) 2007-02-15 2009-11-25 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
MX2009011754A (es) 2007-04-30 2009-12-01 Abbott Lab Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP2010132590A (ja) 2008-12-03 2010-06-17 Astellas Pharma Inc オキサジアゾール化合物
AU2009329345A1 (en) 2008-12-19 2011-06-30 Astrazeneca Ab 1,3,4-oxadiazole derivatives and their uses to treat diabetes

Also Published As

Publication number Publication date
DOP2010000192A (es) 2010-07-15
AU2008339570A1 (en) 2009-07-02
CN101932562A (zh) 2010-12-29
CA2707660A1 (en) 2009-07-02
EP2234978A1 (en) 2010-10-06
BRPI0821274A2 (pt) 2017-06-13
US20090298853A1 (en) 2009-12-03
ECSP10010274A (es) 2010-07-30
AR069802A1 (es) 2010-02-17
EA201001015A1 (ru) 2011-02-28
US7994179B2 (en) 2011-08-09
CN101932562B (zh) 2013-06-12
AU2008339570B2 (en) 2012-04-12
NI201000108A (es) 2012-05-14
CL2008003847A1 (es) 2009-11-27
JP2011507823A (ja) 2011-03-10
NZ586104A (en) 2012-02-24
JP5662803B2 (ja) 2015-02-04
CO6290685A2 (es) 2011-06-20
ZA201003979B (en) 2011-11-30
EP2234978B1 (en) 2015-02-25
ES2535083T3 (es) 2015-05-05
PE20091682A1 (es) 2009-12-04
US20120108602A1 (en) 2012-05-03
IL206045A0 (en) 2010-11-30
TW200932235A (en) 2009-08-01
KR20100099738A (ko) 2010-09-13
WO2009081195A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
ECSP10010561A (es) Pirimidin-5-carboxamidas sustituidas 281
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
PA8791801A1 (es) Compuestos de pirazol
ECSP099721A (es) Inhibidores de cinasa p70 s6
CR10148A (es) Derivados de las benzamidas y heteroarenos
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
GT200600117A (es) Nuevos compuestos farmaceuticos
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
ECSP19051352A (es) Inhibidores selectivos de jak1
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)